|
Genotypes
|
No. of patients
|
No. of Deaths
|
MST (months)
|
Crude HR (95% CI)
|
Adjusted HR (95% CI)a
|
Adjusted P
a
|
|---|
|
TNF-α -308 G>A (rs1800629)
|
|
GG
|
163
|
112 (68.7)
|
23.5
|
1.00
|
1.00
| |
|
AG
|
56
|
39 (69.6)
|
23.2
|
1.04 (0.72-1.50)
|
0.95 (0.65-1.40)
|
0.802
|
|
AA
|
6
|
4 (66.7)
|
18.1
|
1.18 (0.44-3.21)
|
1.10 (0.39-3.11)
|
0.859
|
|
AG+AA
|
61
|
43 (70.5)
|
23.1
|
1.05 (0.74-1.50)
|
0.96 (0.67-1.40)
|
0.849
|
|
AG+GG
|
219
|
151 (68.9)
|
23.4
|
1.00
|
1.00
| |
|
AA
|
6
|
4 (66.7)
|
18.1
|
1.17(0.43-3.16)
|
1.11 (0.40-3.13)
|
0.840
|
|
TNF-α -1031T>C (rs1799964)
|
|
TT
|
137
|
95 (69.3)
|
23.4
|
1.00
|
1.00
| |
|
CT
|
77
|
50 (64.9)
|
22.1
|
0.96 (0.68-1.35)
|
0.89 (0.62-1.28)
|
0.542
|
|
CC
|
11
|
10 (90.9)
|
23.1
|
1.28 (0.67-2.46)
|
1.41 (0.70-2.87)
|
0.341
|
|
CT+CC
|
88
|
60 (68.2)
|
23.1
|
1.00 (0.72-1.38)
|
0.95 (0.68-1.34)
|
0.785
|
|
CT+TT
|
214
|
145 (67.8)
|
23.4
|
1.00
|
1.00
| |
|
CC
|
11
|
10 (90.9)
|
23.1
|
1.30(0.68-2.47)
|
1.46 (0.73-2.94)
|
0.289
|
|
TNFRSF1B +676 T>G (rs1061622)
|
|
TT
|
124
|
85 (68.5)
|
23.4
|
1.00
|
1.00
| |
|
GT
|
90
|
65 (72.2)
|
21.8
|
1.10 (0.80-1.52)
|
1.19 (0.84-1.69)
|
0.323
|
|
GG
|
11
|
5 (45.5)
|
41.1b
|
0.36 (0.14-0.88)
|
0.38 (0.15-0.94)
|
0.037
|
|
GT+GG
|
101
|
70 (69.3)
|
23.2
|
0.96 (0.70-1.31)
|
1.01 (0.72-1.42)
|
0.937
|
|
GT+TT
|
214
|
150 (70.1)
|
22.7
|
1.00
|
1.00
| |
|
GG
|
11
|
5 (45.5)
|
41.1b
|
0.34 (0.14-0.84)
|
0.35 (0.14-0.88)
|
0.026
|
|
TNFRSF1B -1709A>T (rs652625)
|
|
AA
|
207
|
144 (69.6)
|
23.2
|
1.00
|
1.00
| |
|
AT
|
15
|
9 (60.0)
|
27.8
|
0.86 (0.44-1.69)
|
0.85 (0.42-1.71)
|
0.649
|
|
TT
|
3
|
2 (66.7)
|
15.1
|
0.94 (0.23-3.82)
|
1.02 (0.23-4.47)
|
0.976
|
|
AT+TT
|
18
|
11 (61.1)
|
26.7
|
0.88 (0.47-1.62)
|
0.87 (0.46-1.67)
|
0.685
|
|
AT+AA
|
222
|
153 (68.9)
|
23.4
|
1.00
|
1.00
| |
|
TT
|
3
|
2 (66.7)
|
15.1
|
0.95 (0.24-3.85)
|
1.05 (0.24-4.58)
|
0.946
|
|
TNFRSF1B +1663A>G(rs1061624)
|
|
AA
|
67
|
46 (68.7)
|
23.4
|
1.00
|
1.00
| |
|
AG
|
89
|
63 (70.8)
|
21.1
|
1.06 (0.73-1.53)
|
0.98 (0.68-1.43)
|
0.921
|
|
GG
|
62
|
41 (66.1)
|
28.1
|
0.84 (0.56-1.26)
|
0.79 (0.52-1.20)
|
0.269
|
|
AG+GG
|
151
|
104 (68.9)
|
24.0
|
1.03(0.73-1.46)
|
0.96 (0.67-1.37)
|
0.824
|
|
AG+AA
|
156
|
109 (69.9)
|
22.7
|
1.00
|
1.00
| |
|
GG
|
62
|
41 (66.1)
|
28.1
|
0.84 (0.59-1.20)
|
0.81 (0.56-1.18)
|
0.275
|
- MST: median survival time; HR: hazard ratio
-
aAdjusted for age, gender, ethnicity, smoking status, tumor histology, KPS, tumor stage, node status, application of chemotherapy and radiotherapy dose.
-
bMean survival time was provided when MST could not be calculated.
